FBT vs PBE
First Trust NYSE Arca Biotechnology Index Fund against Invesco Biotechnology & Genome ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
45%
16 shared positions
Fee gap
3 bp
FBT is cheaper
1-year return gap
6.8 pts
FBT is ahead
Larger fund
FBT
$2.9B
Side by side
| FBT | PBE | |
|---|---|---|
| Fund | First Trust NYSE Arca Biotechnology Index Fund | Invesco Biotechnology & Genome ETF |
| Issuer | First Trust | Invesco |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.55% | 0.58% |
| Assets | $2.9B | $422M |
| Average daily dollar volume | $20M | $1.7M |
| Listed | Jun 19, 2006 | Jun 23, 2005 |
| FrenzyCap score | 67 | 49 |
| 1-month return | +1.2% | +4.2% |
| 3-month return | +7.2% | +7.0% |
| Year to date | +28.5% | +17.9% |
| 1-year return | +41.3% | +34.5% |
| 30-day volatility | 21.4% | 22.6% |
| Worst drawdown, 1 year | −14.3% | −11.8% |
| Trailing 12-month yield | — | 1.38% |
| Holdings | 32 | 33 |
| Top 10 weight | 43.2% | 48.4% |
| Look-through P/E | 62.4 | 106.3 |
| Holdings vs fair value | +7.1% | +8.1% |
| Holdings above 200-day average | 73% | 78% |
| Net flow, latest 3 reported months | +$2.5M thru Jun 2026 | +$5.9M thru Jul 2026 |
| 30-day implied volatility | 24.8% | 25.9% |
| Holdings as of | as of Jun 30, 2026SEC filing | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
51% of FBT · 61% of PBE
Sector mix of the stock holdings
| Sector | FBT | PBE | Gap |
|---|---|---|---|
| Health Care | 82.4% | 91.3% | −8.9% |
| Technology | 8.2% | 6.2% | +2.1% |
| Industrials | 5.1% | 0.0% | +5.1% |
More: full overlap table · FBT holdings · PBE holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.